These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 39299601)
1. TRIB3 knockdown increases the sensitivity of clear cell renal cell carcinoma to sunitinib by inducing ferroptosis. Chen Z; Jia X; Wang Z; Cai Y; Xu A; Han C; Cheng S; Liu M Cell Signal; 2024 Dec; 124():111421. PubMed ID: 39299601 [TBL] [Abstract][Full Text] [Related]
2. Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression. Chen WJ; Pan XW; Song X; Liu ZC; Xu D; Chen JX; Dong KQ; Di SC; Ye JQ; Gan SS; Wang LH; Zhou W; Cui XG Cancer Lett; 2024 Jul; 593():216963. PubMed ID: 38768682 [TBL] [Abstract][Full Text] [Related]
3. HECTD2 as a target for veratric acid in the regulation of ferroptosis in renal cell carcinoma. Lv D; Xiang Y; Song T; Li J; Chen Y; Huili Y; Shen T Amino Acids; 2024 Sep; 56(1):57. PubMed ID: 39343853 [TBL] [Abstract][Full Text] [Related]
4. SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop. Jiang Z; Yang G; Wang G; Wan J; Zhang Y; Song W; Zhang H; Ni J; Zhang H; Luo M; Wang K; Peng B J Exp Clin Cancer Res; 2024 Oct; 43(1):288. PubMed ID: 39425205 [TBL] [Abstract][Full Text] [Related]
5. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway. Wang H; Zhang L; Liu H; Yang Y; Lu W; Cao X; Yang X; Qin Q; Song R; Feng D; Wang S; Bai T; He J Br J Cancer; 2024 Jul; 131(2):347-360. PubMed ID: 38822145 [TBL] [Abstract][Full Text] [Related]
6. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma. Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837 [TBL] [Abstract][Full Text] [Related]
7. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753 [No Abstract] [Full Text] [Related]
8. ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma. Zhu L; Ding R; Yan H; Zhang J; Lin Z Cell Death Dis; 2020 May; 11(5):337. PubMed ID: 32382017 [TBL] [Abstract][Full Text] [Related]
9. Increased expression of tribbles homolog 3 predicts poor prognosis and correlates with tumor immunity in clear cell renal cell carcinoma: a bioinformatics study. Wu XQ; Tian X; Xu FJ; Wang Y; Xu WH; Su JQ; Qu YY; Zhao JY; Zhang HL; Ye DW Bioengineered; 2022 May; 13(5):14000-14012. PubMed ID: 35726370 [TBL] [Abstract][Full Text] [Related]
10. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance. Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007 [TBL] [Abstract][Full Text] [Related]
11. MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway. Zhang Y; Li Y; Qiu Q; Chen Z; Du Y; Liu X Oxid Med Cell Longev; 2022; 2022():7560569. PubMed ID: 36046690 [TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903 [TBL] [Abstract][Full Text] [Related]
13. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects. Kamli H; Owens EP; Vesey DA; Prasanna R; Li L; Gobe GC; Morais C Biochem Biophys Res Commun; 2022 Jan; 586():42-48. PubMed ID: 34826699 [TBL] [Abstract][Full Text] [Related]
14. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma. D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631 [TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718 [TBL] [Abstract][Full Text] [Related]
16. TRIB3 Promotes the Proliferation and Invasion of Renal Cell Carcinoma Cells via Activating MAPK Signaling Pathway. Hong B; Zhou J; Ma K; Zhang J; Xie H; Zhang K; Li L; Cai L; Zhang N; Zhang Z; Gong K Int J Biol Sci; 2019; 15(3):587-597. PubMed ID: 30745845 [TBL] [Abstract][Full Text] [Related]
17. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway. Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739 [TBL] [Abstract][Full Text] [Related]
18. TAF1D promotes tumorigenesis and metastasis by activating PI3K/AKT/mTOR signaling in clear cell renal cell carcinoma. Hu X; Chen L; Liu T; Wan Z; Yu H; Tang F; Shi J; Chen Z; Wang X; Yang Z Cell Signal; 2024 Dec; 124():111425. PubMed ID: 39307376 [TBL] [Abstract][Full Text] [Related]
19. GABPA inhibits tumorigenesis in clear cell renal cell carcinoma by regulating ferroptosis through ACSL4. Wu Y; Wu Z; Yao M; Liu L; Song Y; Ma L; Liu C Sci Rep; 2024 Nov; 14(1):26521. PubMed ID: 39489850 [TBL] [Abstract][Full Text] [Related]
20. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]